The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

Daniel Castellano(Universidad Complutense de Madrid), H. Cortés-Funes(Centre Hospitalier René-Dubos), Ignacio Escobar(Hospital Universitario 12 De Octubre), Anna Sundlöv(Lund University), A. Rodrı́guez-Antolı́n(Hospital Universitario 12 De Octubre), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre)

The Oncologist

February 1, 2011

10.1634/theoncologist.2010-0154

Cited by 129

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

|Journal of Clinical Oncology|2000|3.8k

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

|The Lancet|2020|1.8k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

|The Lancet Oncology|2017|1.3k